This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

R. Gordon Douglas, Jr, MD

JAMA. 1996;276(22):1796-1798.

Abstract
Pioneering development of the plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to preventive health care of this century. Current and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually eradicate hepatitis B infection from the human population and, with it, many cases of cirrhosis and cancer of the liver.

Author Affiliations
From the Merck Vaccine Division, Merck & Co Inc, Whitehouse Station, NJ.

Footnotes
Reprints: R. Gordon Douglas, Jr, MD, Merck Vaccine Division, Merck & Co Inc, One Merck Dr, PO Box 100, Whitehouse Station, NJ 08889-0100.

A commentary on Buynak EB, Roehm RR, Tyteli AA, Bertiand AU II, Lampson GP, Hilleman MR. Vaccine against human hepatitis B. JAMA. 1976;235:2832-2834.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?